Invivomab polyclonal armenian hamster igg

The neutralizing InVivoMAb anti-mouse IL-1β monoclonal antibody (mAb) (Catalogue#: BE0246) and normal InVivoMAb Polyclonal Armenian Hamster IgG (Catalogue#: BE0091) were purchased from BioXCell. In the GVHD induction model, a total of 400 μg of anti-IL-1β mAb or control IgG was administered intraperitoneally into mice at day −1 day before TBI and every 5 day after TBI.

TCL1-RAB27DKO cells (20 × 10⁶/mouse) were injected (i.v.) in C57BL/6 mice treated with 200 μg (days −2, 0, and 3) and 100 μg (weekly) of either blocking ab against CD8 (InVivoMAb anti-mouse CD8α, #BE0061, RRID:AB_1125541, Bio X Cell) or isotype control (InVivoMAb polyclonal Armenian hamster IgG, #BE0091, RRID:AB_1107773, Bio X Cell) as shown in Fig. 6K.
For the CD8⁺ T-cell transfer experiment, TCL1-RAB27DKO cells (5 × 10⁶/mouse) were injected i.v. (tail vein) in C57BL/6 mice treated with 100 μg (days −1 and 0) of anti-CD8 blocking Ab as shown in Fig. 6M. On day 7, 2 × 10⁶ex vivo ME-sEV–treated CD8⁺ T cells were injected i.p. in each mouse.

Mannan, the ligand antagonist of human mannose receptor; Dextran (MW 20,000, MW 40,000, MW 70,000) were purchased from Sigma-Aldrich (St. Louis, MO). Anti-mouse SIGN-R1 antibody and anti-human DC-SIGN antibody were obtained from Pharmigen (San Diego, CA, USA). For cell culture, all reagents were obtained from Hyclone PRC (gelifesciences/Hyclone), except FBS which was obtained from Zhejiang Tianhang Biotechnologies and antibiotics were obtained from Nalge NUNC, Rochester, NY). For qPCR, all reagents were purchased from Tsingke Biological Technology and Yeasen Biotechnology, PRC. For in vivo studies, InVivoMAb anti-mouse CD209b (SIGN-R1); Clone 22D1, and InVivoMAb polyclonal Armenian hamster IgG were purchased from BioXCell. DNA extraction reagents: Buffer GA, Buffer GB, Buffer GD, Buffer PW, Buffer TE, and Proteinase K were purchased from TIANGEN, PRC.